NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $11.61 -0.23 (-1.94%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$11.64 +0.04 (+0.30%) As of 09/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zevra Therapeutics Stock (NASDAQ:ZVRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range$11.52▼$11.9350-Day Range$9.51▼$13.1852-Week Range$7.51▼$15.03Volume1.48 million shsAverage Volume823,830 shsMarket Capitalization$689.40 millionP/E Ratio12.62Dividend YieldN/APrice Target$27.14Consensus RatingModerate Buy Company Overview Zevra Therapeutics, Inc. is a rare-disease biopharmaceutical company focused on developing and commercializing treatments for conditions with significant unmet medical needs. The company combines data science, patient-focused drug development and traditional pharmaceutical research to advance therapies for rare metabolic and neurological disorders. Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children at least 2 years old, in combination with miglustat. Niemann-Pick disease type C is a rare, progressive genetic disorder that affects the body’s ability to transport cholesterol and other lipids within cells. The company was formed through the combination of Acer Therapeutics and Emalex Biosciences and continues to evaluate additional treatments for rare diseases through its development pipeline. Zevra is led by President and Chief Executive Officer Neil F. McFarlane and is headquartered in the United States. Its commercial and development activities are focused primarily on serving patients with rare diseases in the U.S. and other markets where its therapies may receive regulatory approval.AI Generated. May Contain Errors. Read More Zevra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreZVRA MarketRank™: Zevra Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 29th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingZevra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialZevra Therapeutics has a consensus price target of $27.14, representing about 133.8% upside from its current price of $11.61.Amount of Analyst CoverageZevra Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zevra Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for Zevra Therapeutics are expected to grow by 16.67% in the coming year, from $0.72 to $0.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is 12.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is 12.62, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.09% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 7.46.Change versus previous monthShort interest in Zevra Therapeutics has recently decreased by 10.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentZevra Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zevra Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for ZVRA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,375.00 in company stock.Percentage Held by Insiders3.70% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by Institutions35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVRA Stock News HeadlinesZevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 13, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Zevra Therapeutics to Present at Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comZevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual SymposiumAugust 25, 2026 | quiverquant.comQZevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumAugust 25, 2026 | globenewswire.comRoth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)August 23, 2026 | theglobeandmail.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 21, 2026 | globenewswire.comSee More Headlines ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $8.96 at the start of the year. Since then, ZVRA stock has increased by 29.6% and is now trading at $11.61. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) issued its quarterly earnings results on Wednesday, August, 5th. The company reported $0.25 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. The firm earned $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a trailing twelve-month return on equity of 54.54% and a net margin of 42.82%. Read the conference call transcript. When did Zevra Therapeutics IPO? Zevra Therapeutics (ZVRA) raised $66 million in an initial public offering on Thursday, April 16th 2015. The company issued 5,090,909 shares at $12.00-$14.00 per share. Who are Zevra Therapeutics' major shareholders? Zevra Therapeutics' top institutional investors include Hennion & Walsh Asset Management Inc. (0.65%), Bank of New York Mellon Corp (0.34%), Globeflex Capital L P (0.32%) and Wellington Management Group LLP (0.28%). Insiders that own company stock include Neil F Mcfarlane, Joshua Schafer, R Laduane Clifton, John B Bode, Timothy J Sangiovanni, Thomas Anderson, Adrian W Quartel, Tamara A Favorito and Corey Michael Watton. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA). Company Calendar Last Earnings8/05/2026Today9/19/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ZVRA's financial health is in the Green zone, according to TradeSmith. ZVRA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZVRA CIK1434647 Webwww.zevra.com Phone(321) 939-3416Fax319-665-2577Employees61Year Founded2006Price Target and Rating Average Price Target for Zevra Therapeutics$27.14 High Price Target$35.00 Low Price Target$20.00 Potential Upside/Downside+133.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.92 Trailing P/E Ratio12.62 Forward P/E Ratio16.13 P/E GrowthN/ANet Income$83.23 million Net Margins42.82% Pretax Margin50.92% Return on Equity54.54% Return on Assets34.15% Debt Debt-to-Equity RatioN/A Current Ratio5.17 Quick Ratio5.12 Sales & Book Value Annual Sales$106.47 million Price / Sales6.48 Cash Flow$0.95 per share Price / Cash Flow12.27 Book Value$2.75 per share Price / Book4.22Miscellaneous Outstanding Shares59,380,000Free Float57,187,000Market Cap$689.40 million OptionableOptionable Beta0.95 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ZVRA) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts